White label – Pompe disease - ClinicalTrials.eu

Study of TX000045 for Pulmonary Hypertension in Heart Failure Patients with Preserved Ejection Fraction

Not recruiting

2 1
Investigated Drugs:
- TX000045
+3
Study on the Effects and Safety of Guselkumab for Patients with Active Psoriatic Arthritis

Not recruiting

3 1
Investigated Drugs:
- Guselkumab
+8
Study on the Effectiveness and Safety of Regorafenib for Patients with Metastatic Bone Sarcomas

Not recruiting

2 1 1 1
Investigated Diseases:
Investigated Drugs:
- Regorafenib
Study on Reduced Intensity Radio-Chemotherapy for Stage IIA/B Seminoma Using Etoposide, Cisplatin, and Carboplatin for Patients with Stage IIA/B Seminoma

Not recruiting

2 1 1 1
Investigated Drugs:
Study of Radotinib safety and effectiveness compared to placebo in people with Parkinson’s disease

Not recruiting

2 1
Investigated Drugs:
- Radotinib Dihydrochloride
Study of Nivolumab and Ipilimumab for Patients with Type B3 Thymoma and Thymic Carcinoma After Chemotherapy

Not recruiting

2 1 1 1
Investigated Drugs:
- Ipilimumab
- Nivolumab
Study on the Effectiveness and Safety of Rozanolixizumab for Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)

Not recruiting

3 1 1
Investigated Drugs:
- Rozanolixizumab
+4
Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

Not recruiting

3 1 1 1
Investigated Diseases:
- Plasma cell myeloma
Investigated Drugs:
+8
Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Not recruiting

3 1 1 1
Investigated Diseases:
- Squamous cell carcinoma of head and neck
Investigated Drugs:
- Petosemtamab
- Pembrolizumab
+8
Study of ICT01 and Pembrolizumab for Patients with Advanced-Stage, Relapsed/Refractory Cancer

Not recruiting

2 1 1 1
Investigated Drugs:
- Ict01
- Pembrolizumab

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies